Brief: Acucort Presents Positive Results From Bioequivalence Study
18/01/2019 08:02
Jan 18 (Reuters) - AcuCort AB ACUC.TE :
* POSITIVE RESULTS FROM BIOEQUIVALENCE STUDY
* SAYS DRUG CANDIDATE DEXA ODF IS BIOEQUIVALENT TO COMPARED
REFERENCE PRODUCT
Source text for Eikon: ID:nWkr3d2bTj
Further company coverage: ACUC.TE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on AcuCort AB
See all newsBrief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Acucort AB Acucort Receives Marketing Authorization For Drug Zeqmelit By Norwegian Medicines Agency
Brief: Acucort Receives Marketing Authorization For The Drug Zeqmelit By The Danish Medicines Agency
Brief: AcuCort Is Granted Sme Status By The European Medicines Agency, EMA